Mark Sims US Franchise Head Women’s Cancer & DNA Damage Response AstraZeneca

LYNPARZA Demonstrates Improved Overall Survival in BRCA-Mutated, Platinum-Sensitive Relapsed Ovarian Cancer

MedicalResearch.com Interview with:

Mark Sims US Franchise Head Women’s Cancer & DNA Damage Response AstraZeneca

Mark Sims

Mark Sims
US Franchise Head
Women’s Cancer & DNA Damage Response
AstraZeneca

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: SOLO2 is a Phase III, randomized, double-blind, multicenter trial designed to determine the efficacy and safety of LYNPARZA tablets as a maintenance monotherapy compared with placebo, in patients with platinum-sensitive relapsed or recurrent gBRCA-mutated (BRCAm) ovarian cancer. The trial included 295 patients with germline BRCA1 or BRCA2 mutations who had received at least 2 prior lines of platinum-based chemotherapy and were in complete or partial response. The trial met its primary endpoint in October 2016, showing maintenance treatment with LYNPARZA significantly improved progression-free survival to a median of 19.1 months vs 5.5 months with placebo (a hazard ratio of 0.30; a 95% confidence interval of 0.22 to 0.41; a p value of <0.0001).


MedicalResearch.com:? What are the main findings?

Response: The latest results from SOLO-2 show that patients taking LYNPARZA had a median Overall Survival of 51.7 months vs. 38.8 months for patients on placebo, a difference of nearly 13 months, and reduced the risk of death by 26% (equal to a hazard ratio of 0.74 and p-value of 0.0537; not statistically significant). At five years, 42% of patients who received LYNPARZA were alive versus 33% on placebo, and 22% of patients who began the trial are still receiving treatment with LYNPARZA.

MedicalResearch.com: What should readers take away from your report?

Response: Overall Survival improvements in advanced ovarian cancer have not been seen since the introduction of chemotherapy almost two decades ago. The final Overall Survival analysis from the SOLO-2 trial adds to the broad set of evidence supporting the clinical value of LYNPARZA in women with ovarian cancer.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: The results from this study are promising and further our understanding of LYNPARZA in women with BRCA-mutated, platinum-sensitive relapsed ovarian cancer. We have a broad clinical trial program that will continue to explore how LYNPARZA impacts PARP-dependent tumors across multiple cancer types.

MedicalResearch.com: Is there anything else you would like to add? Any disclosures?

Response: LYNPARZA is the only PARP inhibitor with seven indications across 4 different tumor types: ovarian, breast, pancreatic and prostate cancers. As we continue to follow the science in advancing targeted cancer treatment through biomarker-driven approaches, we hope to meet our goal of maximizing positive outcomes for patients living with DNA-deficient cancers.

Citation: ASCO 2020

Abstract #6002: Final OS results from the Phase III SOLO2 trial for LYNPARZA® (olaparib) maintenance treatment in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer in an oral presentation. LYNPARZA is developed and commercialized in collaboration with Merk & Co., Inc. (Merck: known as MSD outside the US and Canada)

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure,endorse or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.